Results for “hepatitis”
Liver Disease
Liver disease encompasses a broad spectrum of conditions that impair the liver’s structure or function, ranging from acute infections to chronic degenerative disorders.
Health & MedicineCirrhosis
** Cirrhosis is a progressive, irreversible scarring of the liver that replaces healthy tissue with fibrotic tissue and regenerative nodules, ultimately compromising liver function and blood flow. **CONTENT:** ## Overview **Cirrhosis** (also called liver cirrhosis, hepatic cirrhosis, chronic liver failure, or end‑stage liver disease) is the final common pathway of many chronic liver injuries. When hepatocytes are repeatedly damaged—by viral hepatitis, alcohol, non‑alcoholic fatty liver disease (NAFLD), autoimmune disorders, or toxic exposures—the liver attempts to repair itself. This repair process deposits **fibrosis** (scar tissue) and stimulates clusters of surviving hepatocytes to form **regenerative nodules**. Over years, the balance tips toward scar formation, distorting the normal lobular architecture and narrowing the **hepatic sinusoids**, the tiny capillaries that filter blood. The resulting increase in vascular resistance produces **portal hypertension**, while the loss of functional parenchyma impairs metabolism, detoxification, protein synthesis, and bile production. Clinically, cirrhosis may be silent for many years. When symptoms appear, they often reflect complications such as **ascites** (fluid accumulation in the abdomen), **hepatic encephalopathy** (cognitive dysfunction due to toxin buildup), **variceal bleeding** (rupture of enlarged veins in the esophagus or stomach), and coagulopathy (impaired clotting). Diagnosis relies on a combination of laboratory tests (elevated liver enzymes, low albumin, prolonged INR), imaging (ultrasound, CT, MRI), and sometimes liver biopsy. Because the process is largely irreversible, early detection and removal of the underlying cause are essential to halt progression and improve survival. ## History/Background The term “cirrhosis” derives from the Greek *kirrhos* meaning “yellowish,” reflecting the pale, yellow‑tinted appearance of scarred liver tissue noted by early anatomists. Descriptions of liver hardening date back to Hippocrates (5th century BC), but the pathological basis was not clarified until the 19th century, when Rudolf Virchow coined “fibrosis” to describe tissue scarring. In the early 1900s, autopsy studies linked chronic alcohol consumption to cirrhosis, establishing a major etiological link. The discovery of hepatitis B virus (HBV) in 1965 and hepatitis C virus (HCV) in 1989 added viral infection to the list of primary causes. More recently, the rise of obesity and metabolic syndrome has propelled **non‑alcoholic steatohepatitis (NASH)** to become a leading driver of cirrhosis in many countries. ## Key Information - **Etiology:** Chronic alcohol abuse, HBV/HCV infection, NAFLD/NASH, autoimmune hepatitis, primary biliary cholangitis, genetic disorders (e.g., hemochromatosis, Wilson disease), and certain drugs (e.g., methotrexate, amiodarone). - **Pathophysiology:** Ongoing hepatocyte injury → inflammatory cytokine release → activation of hepatic stellate cells → deposition of type I collagen → **fibrosis**. Simultaneous regeneration creates **nodules** that compress sinusoids, raising portal pressure. - **Stages:** Compensated cirrhosis (liver still performs most functions) → decompensated cirrhosis (manifesting ascites, encephalopathy, variceal hemorrhage, jaundice). - **Diagnostic tools:** Serum panels (ALT, AST, bilirubin, albumin, INR), elastography (FibroScan) to measure stiffness, Doppler ultrasound for portal flow, and liver biopsy when non‑invasive tests are inconclusive. - **Management:** Eliminate the inciting cause (abstinence from alcohol, antiviral therapy for HBV/HCV, weight loss for NASH), pharmacologic control of complications (diuretics for ascites, lactulose/rifaximin for encephalopathy, non‑selective beta‑blockers for variceal bleed prophylaxis), and surveillance for hepatocellular carcinoma (ultrasound ± AFP every 6 months). Liver transplantation remains the definitive therapy for end‑stage disease. - **When to seek professional care:** Immediate medical attention is warranted for sudden abdominal swelling, confusion, vomiting blood, or severe jaundice, as these may signal life‑threatening decompensation. ## Significance Cirrhosis is a global health burden, accounting for an estimated 1.5 million deaths annually and ranking among the top causes of disability‑adjusted life years (DALYs) worldwide. Its prevalence mirrors socioeconomic patterns: high rates in regions with endemic viral hepatitis (sub‑Saharan Africa, East Asia) and rising incidence in affluent societies due to NAFLD. The disease’s impact extends beyond individual morbidity; it strains healthcare systems with costly hospitalizations for complications, long‑term medication regimens, and the need for organ transplantation. Public‑health initiatives targeting vaccination against HBV, safe injection practices, alcohol moderation, and obesity prevention have demonstrably reduced cirrhosis incidence in several countries. Moreover, advances in antiviral therapy (direct‑acting agents for HCV) and antifibrotic research hold promise for altering the disease trajectory, underscoring the importance of early detection and multidisciplinary care. **INFOBOX:** - Name: Liver Cirrhosis - Type: Chronic Progressive Liver Disease - Date: First pathological description – 19th century (Virchow) - Location: Worldwide (higher prevalence in regions with viral hepatitis, alcohol misuse, and metabolic disease) - Known For: Irreversible replacement of functional liver parenchyma with fibrotic tissue and regenerative nodules, leading to portal hypertension and liver failure **TAGS:** cirrhosis, liver disease, fibrosis, portal hypertension, hepatitis, alcohol liver disease, non‑alcoholic fatty liver disease, liver transplantation